MX356671B - Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa. - Google Patents

Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.

Info

Publication number
MX356671B
MX356671B MX2013001303A MX2013001303A MX356671B MX 356671 B MX356671 B MX 356671B MX 2013001303 A MX2013001303 A MX 2013001303A MX 2013001303 A MX2013001303 A MX 2013001303A MX 356671 B MX356671 B MX 356671B
Authority
MX
Mexico
Prior art keywords
vivo
inhibition
methods
protein fucosylation
fucose analogs
Prior art date
Application number
MX2013001303A
Other languages
English (en)
Spanish (es)
Other versions
MX2013001303A (es
Inventor
Dennis Benjamin
Peter Senter
Stephen Alley
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2013001303A publication Critical patent/MX2013001303A/es
Publication of MX356671B publication Critical patent/MX356671B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2013001303A 2010-08-05 2011-08-05 Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa. MX356671B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37111610P 2010-08-05 2010-08-05
PCT/US2011/046857 WO2012019165A2 (en) 2010-08-05 2011-08-05 Methods of inhibition of protein fucosylation in vivo using fucose analogs

Publications (2)

Publication Number Publication Date
MX2013001303A MX2013001303A (es) 2014-07-24
MX356671B true MX356671B (es) 2018-06-08

Family

ID=45560106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001303A MX356671B (es) 2010-08-05 2011-08-05 Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.

Country Status (21)

Country Link
US (4) US9504702B2 (cg-RX-API-DMAC7.html)
EP (2) EP3513794A3 (cg-RX-API-DMAC7.html)
JP (4) JP5918235B2 (cg-RX-API-DMAC7.html)
KR (2) KR101950520B1 (cg-RX-API-DMAC7.html)
CN (2) CN103402525B (cg-RX-API-DMAC7.html)
AU (3) AU2011285490B2 (cg-RX-API-DMAC7.html)
CA (1) CA2803388C (cg-RX-API-DMAC7.html)
CY (1) CY1121419T1 (cg-RX-API-DMAC7.html)
DK (1) DK2608796T3 (cg-RX-API-DMAC7.html)
ES (1) ES2711622T3 (cg-RX-API-DMAC7.html)
HU (1) HUE043370T2 (cg-RX-API-DMAC7.html)
IL (2) IL224487A (cg-RX-API-DMAC7.html)
MX (1) MX356671B (cg-RX-API-DMAC7.html)
NZ (1) NZ606250A (cg-RX-API-DMAC7.html)
PL (1) PL2608796T3 (cg-RX-API-DMAC7.html)
PT (1) PT2608796T (cg-RX-API-DMAC7.html)
RU (2) RU2017122482A (cg-RX-API-DMAC7.html)
SI (1) SI2608796T1 (cg-RX-API-DMAC7.html)
TR (1) TR201902439T4 (cg-RX-API-DMAC7.html)
WO (1) WO2012019165A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300653B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2282773B2 (en) 2008-05-02 2025-03-05 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US9504702B2 (en) 2010-08-05 2016-11-29 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
US9328134B2 (en) 2013-02-22 2016-05-03 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CN106699886A (zh) * 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
JP6906520B2 (ja) * 2015-12-04 2021-07-21 シージェン インコーポレイテッド チェックポイント阻害剤と組みわせて２−デオキシ−２−フルオロ−ｌ−フコースを用いる癌治療
ES2908067T3 (es) 2016-05-10 2022-04-27 Ares Trading Sa Métodos para modular los perfiles de galactosilación proteicos de proteínas recombinantes empleando peracetil galactosa
JP2018002666A (ja) * 2016-07-04 2018-01-11 国立研究開発法人理化学研究所 フコース類似体と糖を検出する方法
JP7245177B2 (ja) * 2017-06-07 2023-03-23 シージェン インコーポレイテッド 低減した表面フコシル化を有するｔ細胞、及びそれを作製及び使用する方法
MX2020005662A (es) 2017-12-01 2020-08-20 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
PE20211235A1 (es) 2018-03-29 2021-07-08 Univ California Variantes de lfa3 y composiciones y usos de las mismas
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
WO2020138447A1 (ja) * 2018-12-27 2020-07-02 学校法人慶應義塾 抗ヒトノロウイルス剤
KR20220115998A (ko) * 2019-12-19 2022-08-19 메르크 파텐트 게엠베하 단백질의 글리코실화 프로파일을 조절하기 위한 방법 및 조성물
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
CN116194089A (zh) * 2020-06-03 2023-05-30 西蒙弗雷泽大学 蛋白质岩藻糖基化抑制剂及其用途
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440780A (en) 1979-06-01 1984-04-03 Chevron Research Company Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones
JPH0660189B2 (ja) 1986-01-22 1994-08-10 財団法人微生物化学研究会 ２，６−ジデオキシ−２−フルオロ−ｌ−タロピラノ−ス又はその誘導体とその製造法
FR2630914A1 (fr) 1988-05-04 1989-11-10 Hoechst Sa Laboratoires Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments
KR100211417B1 (ko) 1990-11-30 1999-10-01 유충식 L-탈로피라노시드 유도체 및 그의 제조방법
US5461143A (en) 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5210078A (en) * 1991-04-30 1993-05-11 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
WO1993008205A1 (en) 1991-10-15 1993-04-29 The Scripps Research Institute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of gdp-fucose
WO1995009177A1 (en) 1993-09-29 1995-04-06 Nissin Shokuhin Kabushiki Kaisha 21-substituted steroid compound
US5481143A (en) 1993-11-15 1996-01-02 Burdick; Brian K. Self starting brushless d.c. motor
FR2723947B1 (fr) 1994-08-31 1996-09-27 Adir Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6713287B1 (en) 1995-10-24 2004-03-30 The Scripps Research Institute Enzymatic synthesis of L-fucose and L-fucose analogs
AU5313798A (en) * 1996-10-28 1998-05-22 Novartis Ag Organic compounds
US5770407A (en) 1996-12-10 1998-06-23 The Scripps Research Institute Process for preparing nucleotide inhibitors of glycosyltransferases
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
JPH1135593A (ja) 1997-07-18 1999-02-09 Daikin Ind Ltd ２−フルオロフコシル−ｎ−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP2006515883A (ja) 2003-01-10 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド ２−デオキシグルコースによる癌の処置
WO2006113909A2 (en) 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
ATE474921T1 (de) 2003-06-18 2010-08-15 Chugai Pharmaceutical Co Ltd Fucosetransporter
WO2005035741A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. ゲノムが改変された細胞
BRPI0417750A (pt) 2003-12-23 2007-04-10 Progen Ind Ltd composto da fórmula; composição farmacêutica ou veterinária; uso do composto, e método para prevenção e tratamento na área de glicosaminoglicano (gag) miméticos
DE102004032421A1 (de) 2004-07-05 2006-01-26 Bayer Cropscience Ag Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006067847A1 (ja) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US7700321B2 (en) 2005-10-21 2010-04-20 Genzyme Corporation Antibody-based therapeutics with enhanced ADCC activity
WO2007064448A2 (en) 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
CN104072611A (zh) * 2005-12-21 2014-10-01 维文蒂阿生物公司 与癌症相关的新抗原
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
WO2007095506A1 (en) 2006-02-10 2007-08-23 Invitrogen Corporation Oligosaccharide modification and labeling of proteins
WO2007101148A2 (en) 2006-02-24 2007-09-07 Board Of Regents, The University Of Texas System Hexose compounds to treat cancer
EP1991056A4 (en) 2006-02-24 2009-09-02 Univ Miami MANNOSEDERIVATES FOR THE KILLING OF TUMOR CELLS
JP5885378B2 (ja) 2006-03-22 2016-03-22 ザ スクリプス リサーチ インスティテュート グリコペプチドの調製法
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
US20100150948A1 (en) 2006-10-24 2010-06-17 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
WO2008100453A1 (en) 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
CN101062939A (zh) 2007-05-17 2007-10-31 北京热景生物技术有限公司 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US20110003338A1 (en) 2008-03-11 2011-01-06 Robert Bayer Antibodies with enhanced adcc function
EP2282773B2 (en) 2008-05-02 2025-03-05 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009143078A2 (en) 2008-05-19 2009-11-26 Board Of Regents, The University Of Texas System Methods of treating brain cancer using hexose compounds
EP2303282A4 (en) 2008-05-23 2013-02-13 Univ Miami TREATMENT WITH CONTINUOUS LOW DOSED APPLICATION OF SUGAR ANALOGUE
AU2009268937A1 (en) 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
WO2010111713A2 (en) 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
WO2011137528A1 (en) * 2010-05-06 2011-11-10 Simon Fraser University Methods and compounds for inhibiting glycosyltransferases
US20110288880A1 (en) 2010-05-07 2011-11-24 Patient Care Automation Services, Inc. Targeted health care messaging
US9504702B2 (en) 2010-08-05 2016-11-29 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
JP2014505058A (ja) 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
US8979675B2 (en) 2012-04-25 2015-03-17 Nike, Inc. Golf ball core having radial appendages
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
JP6906520B2 (ja) 2015-12-04 2021-07-21 シージェン インコーポレイテッド チェックポイント阻害剤と組みわせて２−デオキシ−２−フルオロ−ｌ−フコースを用いる癌治療

Also Published As

Publication number Publication date
JP2016175909A (ja) 2016-10-06
JP6622238B2 (ja) 2019-12-18
JP2017149723A (ja) 2017-08-31
EP2608796B1 (en) 2018-11-21
EP3513794A2 (en) 2019-07-24
HUE043370T2 (hu) 2019-08-28
RU2625768C2 (ru) 2017-07-18
WO2012019165A2 (en) 2012-02-09
JP6113887B2 (ja) 2017-04-12
IL244019B (en) 2019-09-26
CA2803388C (en) 2019-11-05
DK2608796T3 (en) 2019-03-18
CN107007615A (zh) 2017-08-04
US20170035790A1 (en) 2017-02-09
RU2017122482A (ru) 2019-01-30
EP2608796A4 (en) 2014-06-11
SI2608796T1 (sl) 2019-03-29
CA2803388A1 (en) 2012-02-09
IL244019A0 (en) 2016-04-21
ZA201300653B (en) 2014-03-26
US20130129784A1 (en) 2013-05-23
CN103402525A (zh) 2013-11-20
EP3513794A3 (en) 2019-10-16
AU2017279653A1 (en) 2018-01-18
US11033561B2 (en) 2021-06-15
JP2020040974A (ja) 2020-03-19
CN103402525B (zh) 2017-03-01
TR201902439T4 (tr) 2019-03-21
RU2013109415A (ru) 2014-09-10
PT2608796T (pt) 2019-02-25
KR20190022884A (ko) 2019-03-06
CY1121419T1 (el) 2020-05-29
AU2016204495A1 (en) 2016-07-21
RU2017122482A3 (cg-RX-API-DMAC7.html) 2019-01-30
PL2608796T3 (pl) 2019-04-30
NZ606250A (en) 2015-04-24
AU2011285490B2 (en) 2016-04-21
EP2608796A2 (en) 2013-07-03
MX2013001303A (es) 2014-07-24
US20200061091A1 (en) 2020-02-27
IL224487A (en) 2016-07-31
KR101950520B1 (ko) 2019-02-20
US20210260086A1 (en) 2021-08-26
WO2012019165A3 (en) 2013-08-15
US10342811B2 (en) 2019-07-09
JP5918235B2 (ja) 2016-05-18
US9504702B2 (en) 2016-11-29
JP2013541503A (ja) 2013-11-14
AU2011285490A1 (en) 2013-01-10
ES2711622T3 (es) 2019-05-06
KR20130135240A (ko) 2013-12-10

Similar Documents

Publication Publication Date Title
MX356671B (es) Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MX341324B (es) Polipeptidos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
PH12013502192A1 (en) Antibodies against human angiopoietin 2
PH12014501108A1 (en) Anti-il-36r antibodies
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX2013012572A (es) Anticuerpos anti-cd40 y metodos de uso.
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2012002459A (es) Metodos de tratamiento usando anticuerpos ldl anti-oxidados.
EP3157554A4 (en) Compositions, methods and therapies for administering antigen peptide
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
FG Grant or registration